The objective of this study was to assess the incidence, risk factors, outcome and impact on OS of pericardial effusion (PEF) in a cohort of 156 pediatric SCT recipients. The mean age was 8.15 ± 6.25 years. In all, 74% of the patients had malignant disease and 35% of the patients received autologous stem cell grafts. Twenty-three subjects developed effusion at 2.75 ± 3.54 months after SCT. The overall probability of developing a PEF after SCT was 16.9%. In the multivariate analysis of risk factors associated with time to PEF, increased age, allogeneic risk status and conditioning type, were all significant factors. In a multivariate analysis of time to death, PEF, CMV status and risk status were all independent risk factors. PEF, however, had the highest HR of 3.334. Of the 23 patients with PEF, 19 died (82.6%); however, none died as a direct result of pericardial tamponade. In summary, our results suggest that PEF is a significant risk factor for post transplant mortality. These results suggest a need for more frequent evaluation and monitoring for development of PEF. Studies are needed to determine the etiology of, and new therapeutic strategies for, PEF in the post-SCT population.
Introduction
SCT is the treatment of choice for a variety of pediatric malignant and non-malignant conditions. 1 Pediatric SCT recipients, however, may develop a variety of side effects and morbidities post-SCT. After SCT, recipients are at risk of non-engraftment, infection, GVHD and other specific organ complications, including cardiac toxicity. One study reported an incidence of life-threatening cardiac toxicity of less than 2% after SCT. 2 Pericardial effusion (PEF), a potentially morbid condition, is becoming a more recognized and frequently described complication that may not be associated with cardiac toxicity per se. [3] [4] [5] [6] [7] [8] [9] [10] PEF after SCT was first reported in 1987 by Veys et al. 10 They reported the case of a young woman with ALL who developed a PEF after conditioning for allogeneic BMT. They theorized that the effusion was secondary to cumulative cardiotoxicity from chemotherapy and radiation therapy. 10 Einsele et al. 3 also reported a patient with acute leukemia who developed a PEF after SCT. This patient, however, developed a PEF later in his post transplant course. At that time, the patient had evidence of both CMV infection and leukemia relapse, which were identified as the etiology of his PEF. 3 There have been numerous other case reports 6, 8, 9 but only one single retrospective review. 5 In this review, Rhodes et al. 5 reported that the incidence of PEF in pediatric recipients after SCT was approximately 4.4%. This study indicated an association between PEF, GVHD and allogeneic SCT. Other suggested etiologies of PEF have included infection, transplant conditioning, hemolytic uremic syndrome and relapsed disease. 4, 7, [11] [12] [13] We therefore conducted a review of 200 consecutive SCTs in 156 pediatric recipients. We determined the time and incidence of PEF, factors associated with PEF and the impact of PEF on OS.
Materials and methods

Patients
We performed a retrospective Institutional Review Boardapproved review of 158 patients who received 200 SCTs at Morgan Stanley Children's Hospital of New York-Presbyterian between 1 January 2000 and 22 September 2005. Two of the 158 patients had a PEF before the transplant and were ineligible for analysis. Allogeneic SCT recipients were defined as either standard or high-risk. High-risk disease was defined as one of the following pre-transplant characteristics: (a) active leukemia in relapse, (b) active leukemia after induction failure, (c) leukemia in third CR or beyond, (d) progressive solid tumor and/or (e) second allogeneic SCT. All patients had to meet the minimum standards for adequate organ function, including appropriate glomerular filtration rate for age and adequate cardiac function measured by echocardiogram as described below.
HLA typing of patient and allogeneic donors HLA typing for patients receiving stem cells from matched family donors or umbilical cord blood donors was performed by serology for HLA-A and -B and by highresolution DNA typing for DRB1 as we previously described. 14 Patients receiving unrelated adult donor PBSCs or BM also had high-resolution DNA typing of HLA-C and HLA-DQB1 as we have previously described.
14 Matched family donors were required to be a 6/6 or 5/6 HLA match, and unrelated umbilical cord blood donor units had to be a 6/6, 5/6 or 4/6 HLA match. Umbilical cord blood donor units were also required to have a minimum of 1.5 Â 10 7 nucleated cells of cryopreserved umbilical cord blood units per kg body weight of the recipient. Unrelated adult donors were required to have a minimum of 5 Â 10 6 CD34 cells/kg and to be an 8/10, 9/10 or 10/10 HLA match (A, B, C, DRB1 and DQB1). For autologous hematopoietic SCT, PBSCs were collected using apheresis. The end point for successful PBSC harvesting was a collection of 5 Â 10 6 CD34 cells/kg. For neuroblastoma patients, in case of detectable tumor cells in the product by immunocytology, CD34 cells were selected using the Isolex 300i system (Baxter Immunotherapy, Round Lake, IL, USA) or the CliniMacs system (Miltenyi Biotec, Auburn, CA, USA). 15 
Conditioning regimens
Conditioning regimens were myeloablative in 71.6% of patients, including all autologous HSCT recipients, and non-myeloablative (reduced intensity allogeneic SCT) in 28.4% (Table 1) . A variety of conditioning regimens were used. Myeloablative regimens consisted primarily of thiotepa/carboplatin, carmustine/etoposide/CY or were based in TBI or BU in combination with CY or melphalan. All RI regimens were fludarabine-based (Table 1) .
Engraftment
Neutrophil engraftment was defined as the first of 3 days after the neutrophil nadir with an ANC 4500/mm 3 . Plt engraftment was defined as the first of three consecutive days showing a plt count X20 000/mm 3 , after a 7-day period of plts being X20 000/mm 3 without transfusions.
GVHD prophylaxis
Tacrolimus and mycophenolate mofetil were administered as GVHD prophylaxis in the majority of allogeneic SCT recipients, as we have previously described. 14 Tacrolimus was administered i.v. at 0.03 mg/kg/day as a continuous infusion or orally at 0.12 mg/kg/day in two divided doses starting on the first day of conditioning or day 1 (protocoldependent). As we previously described, tacrolimus dosing was adjusted to maintain the tacrolimus steady state or trough concentrations of 5-20 ng/mL (whole-blood ELISA). Mycophenolate mofetil was administered daily starting on day 1 at a dose of 15 mg/kg/dose i.v. or orally twice daily, as we previously described. Beginning in January 2002, mycophenolate mofetil doses were adjusted to maintain mycophenolic acid trough concentrations within a reference range of 1-3.5 g/mL. Mycophenolate mofetil dosage was tapered or discontinued as per individual protocol, but not before day 28. Other GVHD prophylaxis regimens included CYA/methylprednisolone, CYA/methotrexate and CYA/ methylprednisolone/methotrexate. GVHD was graded according to the Glucksberg and Seattle consensus criteria. 16 The 'rule of 9' or burn chart was used to estimate the extent of skin rash. If a clinical diagnosis of acute GVHD (aGVHD) or chronic GVHD (cGVHD) was made, histological confirmation was obtained whenever possible.
Supportive care
All patients were hospitalized in protective isolation, defined as single hospital rooms with high-efficiency particulate air filtration system and reverse isolation requiring strict hand degerming and use of masks by staff for unrelated HSCT patients. Beginning in January 2001, liposomal amphotericin B (3 mg/kg/day i.v. over 2 h) was administered to all patients who received allogeneic SCT starting on day 0 until day 100, as we previously described. 17 Fluconazole was used as anti-fungal prophylaxis for the remaining patients. Additional anti-infective prophylaxis against Pneumocystis carinii pneumonia, HSV and CMV, if indicated, was administered, as we have previously described. 18 All patients received hematopoietic growth factors starting with sargramostim (GM-CSF 250 mg/m 2 /day i.v. daily) on day 0 within 3 h of stem cell infusion and continued until WBC count was 0.3 Â 10 9 cells/L for two consecutive days. Patients were then switched to filgrastim (G-CSF 10 mcg/kg/day i.v. daily) and tapered by 50% when the ANC reached 42.5 Â 10 9 cells/L for two consecutive days, as we previously described. 19 Cardiovascular surveillance Two-dimensional echocardiograms (Hewlett Packard Philips Sonos 5500 or 7500, Philips Medical Systems, Andover, MA, USA) were performed uniformly at baseline before each SCT and when patients had symptoms and/or signs of cardiac or pericardial disease post-SCT. Signs and symptoms prompting examination with echocardiogram included, but were not limited to, changes in basal heart rate, pulse pressure, blood pressure, shortness of breath, oxygen desaturation and/or chest pain. A single member (CK) of the Pediatric Cardiology Department reviewed all echocardiograms. The cardiologist reviewing the echocardiograms, although aware of the clinical status of the patients, was blinded to all other associated complications. PEF was defined as a recognizable accumulation of fluid within the pericardial space, resulting in a clear space between the visceral and parietal pericardium. The assessment of PEF was at best semi-quantitative, but was most often qualitative. Patients were enrolled in the study on meeting the eligibility criteria of shortening fraction of X25-28% by echocardiogram, or ejection fraction of X45-48% by radionuclide angiogram or echocardiogram and no evidence of PEF.
Statistical analysis
Continuous variables were presented as mean±s.d., and categorical variables were presented as percentages. Kaplan-Meier curves were constructed for the time to appearance of PEF and time to death. The univariate and multivariate Cox proportional hazards models were used to examine the effect of each covariate on time to effusion and time to death. aGVHD and cGVHD were treated as timedependent covariates. Only subjects who had an allogeneic SCT were considered whenever aGVHD or cGVHD was involved (n ¼ 102). In time to death analysis, effusion status was also treated as a time-dependent covariate. The covariates analyzed for risk to develop PEF and time to death included older age (continuous variable), gender, ethnicity, CMV status, ablative conditioning, allogeneic transplant, aGVHD or cGVHD, number of transplants, malignant disease, high-risk, unrelated cord blood donor source and degree of matching (6/6 or 10/10 vs o6/6 or o10/10). In addition, presence of PEF was included in the analysis for time to death. Those covariates with a P-value of o0.2 were included in the final multivariate Cox proportional hazards model. All statistical analyses were performed using SAS Version 9.1 Software (SAS Institute, Cary, NC, USA). The significance level was set to be 0.05. Table 2 . The mean follow-up time was 978.6 ± 838.3 days. The mean age was 8.15±6.25 years, male to female ratio was 56 vs 44%. In all, 74% had malignant disease; 35% received autologous stem cell grafts and among the other 65% who received allogeneic grafts, 36% were X1 Ag mismatched.
Results
Patient demographics
Engraftment
Among 156 subjects, 138 subjects (88.46%) achieved neutrophil engraftment at a mean ± s.d. of 17.33 ± 11.42 days after transplant, and 105 subjects (67.31%) achieved plt engraftment at a mean±s.d. of 32.25±38.56 days after transplant. (Table 3b) . TBI as part of the conditioning regimen was an independent risk factor for development of PEF. In the patients who received TBI as part of their conditioning regimen, the rate of PEF was 39.38%. In the group of patients who did not receive TBI, the rate of developing PEF was 15.59% (P ¼ 0.027). The HR of TBI in the univariate Cox proportional hazards model was significant, with a value of 3.43, 95% CI 1.38-8.52 (P ¼ 0.008), but the HR was not significant in multivariate analysis after adjusting for age, race/ethnicity, risk, donor source and match, HR ¼ 1.47, 95% CI 0.53-4.06 (P ¼ 0.46).
Of the 23 patients with PEF, 19 died (82.6%); however, none died as a direct result of pericardial tamponade and/ or surgical therapeutic intervention. Six patients who developed PEF after SCT required mechanical intervention for decompression of the effusion. Three of those patients underwent surgical intervention with a pericardial window, while three patients underwent pericardiocentesis. Five of the patients who required pericardiocentesis post-SCT had microbiological studies sent and all were negative for bacterial, viral and fungal cultures. Given the very small number of patients who had PEF sent for analysis, we are unable to draw any conclusions or detect any trends in the WBC count or protein of the fluid. All patients who required surgical intervention for the PEF eventually died; Months after SCT Probability of developing effusion Pericardial effusion in pediatric SCT recipients M Neier et al however, none of them died as a direct result of tamponade. In the entire group of patients with PEF, deaths were attributed to infection/sepsis (n ¼ 5), GVHD (n ¼ 3), persistent disease (n ¼ 8) and multi-organ failure (n ¼ 3). The characteristics of the patients with PEF are summarized in Table 4 . Six of the patients with PEF who died had autopsies performed. The results are summarized in Table 5 .
Survival
Risk factors associated with survival. The mean follow-up of all subjects after SCT was 978.60 ± 838.29 days. The probability of 3-year OS was 52.44% (95% CI 45.1-61.0%) (Figure 2 ). There was a significant difference in OS between patients with and without development of PEF as shown in Figure 2 . PEF, as a time-dependent variable, had the highest HR of 3.345, 95% CI 1.76-6.35 (P ¼ 0.0002).
In the univariate analysis of risk of death (Table 6a) , there were many factors that were significant (Po0.2). Presence of PEF was the most significant risk factor for time to death with a P-value of o0.0001. Consistent with known risk factors for transplant, increased age, CMV status, transplant type (allogeneic), presence of cGVHD, high-risk status, donor source (umbilical cord blood) and match (o6/6 or o10/10) were all significant risk factors for time to death. In a multivariate analysis of time to death, PEF, CMV status and high-risk status all remained as independent risk factors. In a multivariate analysis of risk of death (Table 6b) , PEF was the most significant risk factor (HR: 3.345, 95% CI 1.76-6.35) with a P-value of 0.0002. Positive CMV status and poor risk were also significant risk factors for time to death, with Po0.03 and Po0.02, respectively.
Discussion
As previously mentioned above, PEF has become a more recognized complication after SCT. In this study, we evaluated multiple factors that may contribute to the development of and risk of mortality from PEF post-SCT. We have conducted the largest study to date evaluating the role of PEF in pediatric SCT recipients. The probability of developing PEF was 16.9% overall, 17.6% in our patients receiving allogeneic SCT and 9.3% in those receiving autologous SCT. This was much higher than the 4.4% of patients previously described by Rhodes et al. 5 Rhodes et al., 5 however, included only those patients with clinically significant PEF post-SCT. 5 This previous study differs from ours in that we included all patients with PEF detected on echocardiography irrespective of whether or not they were clinically relevant. As so many SCT patients with PEF may be asymptomatic and additionally may not be routinely screened with echocardiograms, we theorize that this may be an under-diagnosed or under-recognized complication of SCT. If detected, however, PEF may be an important indicator of increased risk of morbidity and mortality post-SCT.
Given the myriad of complications after SCT, it is difficult to tease out the risk factors associated with the development of PEF. As mentioned earlier, other studies have implicated allogeneic donor source, GVHD, infection and/or relapsed malignant disease as risk factors for developing PEF post-SCT. 4, 5, 7, [11] [12] [13] We evaluated these and other risk factors using univariate and multivariate analysis. Risk factors typically associated with a worse prognosis were also associated with a risk for developing PEF. We found that increased age, high-risk status and ablative conditioning type were all significant risk factors contributing to the development of effusion. In addition, TBI-based conditioning was an independent risk factor for development of PEF.
Increased age has previously been shown to be a risk factor for SCT recipients, [20] [21] [22] and it was a statistically significant risk factor for development of PEF in this study. We evaluated age as a continuous variable with increased risk as age increased. There are no large studies, however, evaluating the development of PEF in adult recipients. Our data suggest that there is a need to monitor and report PEF in adult and pediatric SCT recipients.
We defined high-risk patients to be those having (a) active leukemia in relapse, (b) active leukemia following induction failure, (c) leukemia in third CR or beyond, (d) progressive solid tumor and/or (e) second allogeneic SCT. In our study, poor risk status was a significant risk factor for development of and risk of death from PEF after SCT. This was similar to the data taken from other studies that showed high-risk factors to increase a patient's risk of relapse and death. 23 Ablative conditioning was noted in our data to be an important risk factor for the development of PEF in SCT recipients. Our group recently summarized the experience Pericardial effusion in pediatric SCT recipients M Neier et al of reduced intensity allogeneic SCT in pediatric recipients. 24 We hypothesized that the risk of both aGVHD and cGVHD may be lower in recipients of reduced-intensity conditioning transplants and that the risk of bacterial infections may also be lower in the peri-transplant period after reduced-intensity conditioning. There may be an increased risk, however, of viral and fungal infections because of the increased need for immunosuppression in these patients. Patients in our study who received ablative conditioning were at higher risk for development of PEF; this may be related to the increased risk of GVHD in these patients. Given that patients who receive ablative conditioning regimens are more likely to receive TBI, and TBI was an independent risk factor for development of PEF, TBI may be the inciting factor predisposing these patients to PEF.
In our study, PEF had the most significant impact on risk of death post-SCT. CMV status and poor risk status, however, were also significant risk factors for mortality. Although CMV status increased the risk of death, there was no increased risk of development of PEF. As testing for CMV changed over the course of our study, we chose to evaluate patients based on their CMV status measured with titers rather than levels of infection/disease with PCR methods. One patient with a PEF, however, had clear evidence of active CMV disease. CMV reactivation has previously been shown to be a known risk factor for mortality in allogeneic SCT recipients. 25 As previously described, our group used a prophylactic regimen of alternative day ganciclovir and foscarnet to prevent CMV activation in allogeneic SCT recipients. 18 It may be that there is a common interplay of host factors and donor factors contributing to mortality in patients with PEF in SCT recipients.
Given the relatively early incidence of PEF, it may be a manifestation of aGVHD in patients receiving allogeneic transplantation. GVHD is often associated with a cytokine surge that could be the inciting factor for the development of PEF. 26 For example, Carlson et al. 27 described the association between differentiated Th17 cells and the Pericardial effusion in pediatric SCT recipients M Neier et al development of a lethal form of GVHD If development of PEF is indeed related to aGVHD, however, it is more difficult to understand why patients receiving autologous SCT experience PEF. It is impressive to note that in Rhodes' review, all patients with PEF had aGVHD or cGVHD. 5 The patients with clinically insignificant PEF may also be experiencing a subacute or milder form of GVHD. Alternatively, PEF may be a harbinger of development of GVHD. We hypothesize that PEF post-SCT may be related to a cytokine surge, regardless of the presence of aGVHD. This needs to be evaluated prospectively. In future prospective studies, it would be helpful to measure either the amount of serum cytokines or, in patients requiring intervention, the amount of cytokines in the pericardial fluid.
Another possible explanation for the development of PEF post-SCT may be the large volume of i.v. fluids many of these patients receive. It is not feasible, however, to delineate the exact amount of fluids any patient received in the peri-transplant period. In addition, we did not note an increased amount of peripheral edema that would be related to fluid overload syndromes. Given the limitations of a retrospective study, it is not possible to quantify the exact amount of fluid intake each patient had 48-72 h before developing a PEF. Other authors have postulated infectious etiologies for development of PEF. 28, 29 However, we did not note an increased risk of CMV in patients developing PEF. Not all patients were routinely screened for other viral infections such as adenovirus, so it was not possible to include this as a risk factor. However, in evaluating the patients with clinically significant PEF requiring intervention, we did not note a trend towards increased serious bacterial or viral infections.
There are some notable limitations with this study. Given the nature of pediatric SCT programs, this is a very heterogeneous population; for example, there are patients with both malignant and non-malignant diseases. In order to evaluate a more uniform population with significant numbers, one would need to perform a multi-institutional study. In addition, as this was a retrospective study, there were no standardized time points for performing routine echocardiograms. Given this limitation, we may have underestimated the number of patients with asymptomatic PEF as well as the timing of the onset of the PEF. As this was a retrospective study, there were some factors that we were unable to evaluate, such as total anthracyline dose; however, cumulative exposure to anthracyclines was limited to o350 mg/m 2 . Another limitation of this study is that there was no standard timing of post-HSCT echocardiograms. In future studies, we would strongly consider performing echocardiograms at day þ 30, þ 60 and þ 100 after HSCT.
While the etiology of PEF and its impact on mortality post-SCT is unclear, we are convinced that it is imperative to initiate closer screening for the development of PEF. We propose that patients with PEF may need closer monitoring for the development of GVHD or other complications. As most of these patients have clinically insignificant PEF, it is typically not necessary to surgically intervene. It could be important, though, to begin prospective studies to evaluate more closely the etiology of PEF and possible interventions to decrease mortality, such as more frequent screening with echocardiogram.
